ROS1 rearrangement / fusion

ROS1 gene rearrangements detected by FISH, immunohistochemistry or sequencing; used as a predictive marker for ROS1-directed tyrosine kinase inhibitors in non-small cell lung cancer.

CI-BIO-00000014ROS1 graph →NCIt C131071 Tumor-agnostic · 4 approval rows

Also calledROS1-positive · ROS1 rearrangement · CD74-ROS1

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Entrectinib EU EMA · Jul 31, 2020 · drug in derived setRegulatory approved
Entrectinib US FDA · Oct 20, 2023 · drug in derived setRegulatory approved
Entrectinib US FDA · Aug 15, 2019 · drug in derived setRegulatory approved
Repotrectinib EU EMA · Jan 13, 2025 · matched on indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (11)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	19	19	—	—	6 / 0 / 1 / 12 / 0
Lung Adenocarcinoma	5	5	—	—	0 / 0 / 4 / 1 / 0
Inflammatory Myofibroblastic Tumor	3

Derived

Drugs with predictive evidence (10)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CrizotinibSmall Molecule	17	9	8	A	9 / 15	Colorectal Adenocarcinoma, Inflammatory Myofibroblastic Tumor, Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma +2
EntrectinibSmall Molecule	8	8	—	A	8 / 0	Desmoplastic Infantile Astrocytoma, Diffuse Midline Glioma, H3 K27-Altered, Inflammatory Myofibroblastic Tumor, Low Grade Glioma +2
ForetinibSmall Molecule	5	4	1	D	8 / 2	Lung Non-Small Cell Carcinoma
LorlatinibSmall Molecule	3	3	—	D	5 / 0	Glioblastoma, Lung Non-Small Cell Carcinoma
CabozantinibSmall Molecule	2	2	—	D	4 / 0	Lung Non-Small Cell Carcinoma
CeritinibSmall Molecule	2	1	1	C	1 / 2	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma
ALK Inhibitor TAE684	1	—	1	D	0 / 2	Lung Non-Small Cell Carcinoma
AZD3463	1	—	1	D	0 / 2	Lung Non-Small Cell Carcinoma
BrigatinibSmall Molecule	1	—	1	D	0 / 2	Lung Non-Small Cell Carcinoma
DS-6501b	1	1	—	D	2 / 0	Lung Adenocarcinoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (35)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–35 of 35 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ROS1 Fusion8
Crizotinib	Colorectal Adenocarcinoma	Predictive	E	Supports Sensitivity Response	2	accepted	EID1301 A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Bre… (full text at CIViC) PMID 24296758 · Aisner et al., 2014 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID688 An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were t… (full text at CIViC) PMID 25264305 · Shaw et al., 2014 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID1030 In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses incl… (full text at CIViC) PMID 25667280 · Mazières et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID7282 In the ongoing phase 1 study PROFILE 1001, NSCLC patients with ROS1 rearrangement confirmed by FISH or RT-PCR received crizotinib 250mg twice daily. Among 53 patients, the ORR was 72% (95% CI, 58% to … (full text at CIViC) PMID 30980071 · Shaw et al., 2019 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID7933 A phase 2 clinical trial studied the efficacy of Crizotinib in East Asian NSCLC patients positive for ROS1 rearrangements (detected by RT-PCR AmoyDx assay) and negative for ALK1 rearrangements. Of the… (full text at CIViC) PMID 29596029 · Wu et al., 2018 · Open in CIViC	civic
Entrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID2951 Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrec… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID11123 Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in ROS-1 fusion-positive NSCLC (locally advanced or metastat… (full text at CIViC) PMID 31838015 · Drilon et al., 2020 · Open in CIViC	civic
Crizotinib	Minimally Invasive Lung AdenocarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1443 Study describes a 31-year old male, never-smoker patient with advanced NSCLC. Testing did not indicate tumor had EGFR mutation or ALK rearrangement. First line erlotininb did not yield a response. Aft… (full text at CIViC) PMID 22215748 · Bergethon et al., 2012 · Open in CIViC	civic
ROS1 Fusion1
Entrectinib	Desmoplastic Infantile AstrocytomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11850 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
ROS1 Fusion3
Entrectinib	Diffuse Midline Glioma, H3 K27-Altered	Predictive	C	Supports Sensitivity Response	3	accepted	EID11849 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Low Grade Glioma	Predictive	C	Supports Sensitivity Response	1	accepted	EID11855 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (8 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Melanoma	Predictive	C	Supports Sensitivity Response	4
ROS1 e7::e351
Lorlatinib	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID7483 Ectopic expression of GOPC–ROS1 in Ba/F3 cells induced cytokine-independent growth whereas overexpression of ROS1 alone did not. Using a series of tyrosine kinase inhibitors, lorlatinib was the most e… (full text at CIViC) PMID 30171048 · Davare et al., 2018 · Open in CIViC	civic
ROS1 Fusion3
Crizotinib	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response	3	accepted	EID1444 Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-R… (full text at CIViC) PMID 24875859 · Lovly et al., 2014 · Open in CIViC	civic
Entrectinib	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response	2	accepted	EID11860 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with inflammat… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response
ROS1 Fusion1
Ceritinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID1248 Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing aft… (full text at CIViC) PMID 26917690 · Subbiah et al., 2016 · Open in CIViC	civic
ROS1 Fusion + ROS1 G2032R6
Crizotinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	4	accepted	EID1100 Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mut… (full text at CIViC) PMID 23724914 · Awad et al., 2013 · Open in CIViC	civic
Cabozantinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1101 Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival o… (full text at CIViC) PMID 25351743 · Katayama et al., 2015 · Open in CIViC	civic
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER
ROS1 Fusion1
Crizotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1690 In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a de… (full text at CIViC) PMID 25922291 · Le et al., 2015 · Open in CIViC	civic
ROS1 G2032R1
Crizotinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	1	accepted	EID2934 Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistan… (full text at CIViC) PMID 23724914 · Awad et al., 2013 · Open in CIViC	civic
ROS1 G2032R + ROS1 Fusion1
DS-6501b	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID7538 In preclinical models, DS-6051b inhibited tumour growth and phospho-ROS1 levels in CD74-ROS1 G2032R mutant Ba/F3 cells. Similar results were seen in the crizotinib-resistant patient derived MGH047-4 c… (full text at CIViC) PMID 31399568 · Katayama et al., 2019 · Open in CIViC	civic
ROS1 Fusion + ROS1 L2026M4
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID1252 Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cel… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID1257 Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
Foretinib	Lung Non-Small Cell Carcinoma
ROS1 Fusion + ROS1 G2101A2
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID1259 Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
Foretinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1260 Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
ROS1 Fusion + ROS1 L2155S1
ALK Inhibitor TAE684 + Crizotinib + ForetinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID1256 The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
ROS1 G2032R + ROS1 Fusion1
Lorlatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1251 Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC	civic
ALK Fusion + ROS1 FusionALK ROS11
Crizotinib	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID11671 This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC) PMID 35233056 · Mansfield et al., 2022 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (63)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Entrectinib	EU EMA	Tumor-agnosticLung Non-Small Cell Carcinoma	Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional	approved	Jul 31, 2020	ema
Entrectinib	US FDA	Tumor-agnostic	Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.accelerated	approved	Oct 20, 2023	openfda

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (64)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 24 recruiting · 17 active phase 3 · 172 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 64 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05136196	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	recruiting	Phase 2	150	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	active not recruiting	N/A	7,458	National Cancer Institute (NCI)NIH	3	Sep 23, 2026	clinicaltrials
NCT03899155	Pan Tumor Rollover Study	recruiting	Phase 2	1,500	Bristol-Myers SquibbINDUSTRY	38	Sep 23, 2026	clinicaltrials
NCT05144997	Lorlatinib Continuation Study	active not recruiting	Phase 4	76	PfizerINDUSTRY	8	Sep 23, 2026	clinicaltrials
NCT07405164	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	recruiting	Phase 3	450	Merck Sharp & Dohme LLCINDUSTRY	22	Sep 23, 2026	clinicaltrials
NCT06140836	A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)	active not recruiting	Phase 3	190	Bristol-Myers SquibbINDUSTRY	21	Sep 22, 2026	clinicaltrials
NCT07816380	A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer	not yet recruiting	Phase 3	216	Guangzhou JOYO Pharma Co., LtdINDUSTRY	0	Sep 22, 2026	clinicaltrials
NCT04302025	A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1)	recruiting	Phase 2	99	Genentech, Inc.INDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT01708954	Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer	active not recruiting	Phase 2	125	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT05502315	Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY)	active not recruiting	Phase 2	47	Rana McKay, MDOTHER	1	Sep 8, 2026	clinicaltrials
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST)	active not recruiting	Phase 2 / Phase 3	1,000	Hoffmann-La RocheINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT05862285	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX)	recruiting	Phase 3	100	Hoffmann-La RocheINDUSTRY	15	Sep 2, 2026	clinicaltrials
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	Phase 2	6,452	National Cancer Institute (NCI)NIH	3	Aug 28, 2026	clinicaltrials
NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2)	active not recruiting	Phase 2	534	Hoffmann-La RocheINDUSTRY	16	Aug 25, 2026	clinicaltrials
NCT05039281	Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma	active not recruiting	Phase 1 / Phase 2	47	M.D. Anderson Cancer CenterOTHER	1	Aug 25, 2026	clinicaltrials
NCT07784959	Study of NXP900 With Lorlatinib in ALK+ Lung Cancer	recruiting	Phase 1	54	Nuvectis Pharma, Inc.INDUSTRY	1	Aug 25, 2026	clinicaltrials
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	enrolling by invitation	Phase 3	5,000	ExelixisINDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT04603807	A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases	active not recruiting	Phase 3	217	Hoffmann-La RocheINDUSTRY	18	Aug 13, 2026	clinicaltrials
NCT06007937	A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer	active not recruiting	Phase 1 / Phase 2	9	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 13, 2026	clinicaltrials
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)(HORIZON 1)	active not recruiting	Phase 3	68	Hoffmann-La RocheINDUSTRY	19	Aug 5, 2026	clinicaltrials
NCT01639508	Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity	recruiting	Phase 2	86	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 4, 2026	clinicaltrials
NCT05663710	Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC	recruiting	Phase 1 / Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Jul 30, 2026	clinicaltrials
NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B)	active not recruiting	Phase 3	1,000	Hoffmann-La RocheINDUSTRY	24	Jul 24, 2026	clinicaltrials
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	active not recruiting	Phase 1	5	City of Hope Medical CenterOTHER	1	Jul 1, 2026	clinicaltrials
NCT06333899	Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	recruiting	Early Phase 1	15	Nationwide Children's HospitalOTHER	6	Jun 29, 2026	clinicaltrials
NCT06813079	Using Tumor Models to Determine Treatments	recruiting	Phase 2	25	University Health Network, TorontoOTHER	1	Jun 23, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Jun 22, 2026	clinicaltrials
NCT06026410	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001)	recruiting	Phase 1	300	Kura Oncology, Inc.INDUSTRY	5	Jun 8, 2026	clinicaltrials
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	active not recruiting	Phase 1	8	National Cancer Institute (NCI)NIH	1	May 28, 2026	clinicaltrials
NCT03611738	Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC	active not recruiting	Phase 1	21	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	May 15, 2026	clinicaltrials
NCT07415005	Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer	recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	May 5, 2026	clinicaltrials
NCT06564324	A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients	recruiting	Phase 3	194	Nuvation Bio Inc.INDUSTRY	1	Apr 13, 2026	clinicaltrials
NCT06282874	Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases	active not recruiting	Phase 4	41	Guangdong Association of Clinical TrialsOTHER	1	Apr 9, 2026	clinicaltrials
NCT04963283	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	active not recruiting	Phase 2	48	University of Colorado, DenverOTHER	1	Mar 31, 2026	clinicaltrials
NCT05160922	Crizotinib Continuation Clinical Study	active not recruiting	Phase 4	27	PfizerINDUSTRY	5	Mar 30, 2026	clinicaltrials
NCT05100069	Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer	recruiting	—	500	TakedaINDUSTRY	1	Mar 17, 2026	clinicaltrials
NCT04091750	Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma	active not recruiting	Phase 2	14	Georgetown UniversityOTHER	1	Mar 3, 2026	clinicaltrials
NCT05721950	A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)(Brilliant)	active not recruiting	—	154	TakedaINDUSTRY	1	Feb 18, 2026	clinicaltrials
NCT04223596	Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients(CUBIK)	active not recruiting	Phase 2	33	Fundación GECPOTHER	1	Feb 4, 2026	clinicaltrials
NCT05740943	Induction Lorlatinib in Stage III Non-small Cell Lung Cancer	active not recruiting	Phase 2	48	Guangdong Provincial People's HospitalOTHER	1	Jan 20, 2026	clinicaltrials
NCT02201992	Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	active not recruiting	Phase 3	166	ECOG-ACRIN Cancer Research GroupNETWORK	3	Dec 19, 2025	clinicaltrials
NCT04925609	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors(Briga-PED)	recruiting	Phase 1 / Phase 2	65	Princess Maxima Center for Pediatric OncologyOTHER	2	Dec 5, 2025	clinicaltrials
NCT04204850	Cabozantinib to Treat Recurrent Liver Cancer Post Transplant	recruiting	Phase 2	20	University Health Network, TorontoOTHER	1	Dec 3, 2025	clinicaltrials
NCT03052608	A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	active not recruiting	Phase 3	296	PfizerINDUSTRY	23	Nov 25, 2025	clinicaltrials
NCT05770544	DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Nov 24, 2025	clinicaltrials
NCT05200481	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)(MP-ALK)	active not recruiting	Phase 2	110	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Nov 17, 2025	clinicaltrials
NCT03707938	Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer	active not recruiting	Phase 1	35	M.D. Anderson Cancer CenterOTHER	1	Nov 3, 2025	clinicaltrials
NCT02767804	eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients	active not recruiting	Phase 3	290	Xcovery Holdings, Inc.INDUSTRY	20	Oct 14, 2025	clinicaltrials
NCT07199959	Study on the Mechanism of Acquired Resistance of Entrectinib	recruiting	—	38	Fudan UniversityOTHER	1	Sep 30, 2025	clinicaltrials
NCT03170960	Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	914	ExelixisINDUSTRY	9	Aug 17, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (11)

Drugs with predictive evidence (10)

Predictive evidence items (35)

Approvals mentioning the linked drugs (63)

Active trials (64)

Linked publications (20)